• Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that supports the targeted, prophylactic immunosuppression regimen in the ongoing pheEDIT gene editing clinical trial in adults with phenylketonuria (PKU) and juMPStart gene therapy trial in adults with Hunter syndrome (MPS II). (advfn.com)
  • We are pleased to share our work outlining the impact immunosuppression regimens had on outcomes following AAVHSC dosing in NHPs, as it contributes to a key area of research in the gene therapy and gene editing field," stated Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. (advfn.com)
  • Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today six presentations supporting its gene editing, gene therapy and GTx-mAb programs at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting. (biospace.com)
  • Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the "Class Period"), of the important May 24, 2022 lead plaintiff deadline . (globenewswire.com)
  • Homology Medicines, Inc. (NASDAQ: FIXX)'s merger with Q32 Bio Inc. Upon completion of the proposed transaction, Homology shareholders are expected to own approximately 25% of the combined company. (fox40.com)
  • There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Homology Medicines. (historicalperatio.com)
  • On this page we presented the FIXX Historical PE Ratio information for Homology Medicines' stock. (historicalperatio.com)
  • That's why we bring you Historical PE Ratio .com to make it easy for investors to investigate Homology Medicines PE history or the past PE information for any stock in our coverage universe. (historicalperatio.com)
  • The tables below show price targets and recommendations from analysts covering HOMOLOGY MEDICINES INC. (stocknews.com)
  • In terms of how HOMOLOGY MEDICINES INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -2486.14% of that group. (stocknews.com)
  • HOMOLOGY MEDICINES INC's number of analysts covering the stock is greater than 2129.31% of stocks in the small market cap category. (stocknews.com)
  • In terms of how HOMOLOGY MEDICINES INC fares relative to Healthcare stocks, note that its average analyst price target is higher than 523.25% of that group. (stocknews.com)
  • Stocks similar to HOMOLOGY MEDICINES INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are BTAI , MBIO , and ACET . (stocknews.com)
  • Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, and Homology Medicines Inc. (Nasdaq: FIXX) ("Homology"), a genetic medicines company, announced today that the companies have agreed to establish a high-performing, full scope Adeno-Associated Virus (AAV) Manufacturing and Innovation Business in the US. (oxb.com)
  • Accessing Homology Medicines' unique AAV capabilities is a major advancement in Oxford Biomedica's goal to become an innovative global viral vector leader that provides solutions to Cell and Gene Therapy (C>) Biotech and Biopharma companies for their process development and manufacturing needs across key viral vectors. (oxb.com)
  • 60 million in Bedford, Mass.-based Homology Medicines (Nasdaq: FIXX), a clinical-stage genetic medicines company focused on treatments for rare genetic diseases with significant unmet medical needs. (pfizer.com.sg)
  • $FIXX -5.6% Homology Medicines Announces World's First Gene Editing Clinical Trial for PKU. (bpiq.com)
  • Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the second quarter ended June 30, 2023. (biospace.com)
  • VBI Vaccines Inc. ( NASDAQ: VBIV ) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today provided a corporate update, outlook for 2019, and announced its financial results for the fourth quarter and twelve months ended December 31, 2018. (vbivaccines.com)
  • ET to report second quarter 2023 financial results and provide a corporate update. (biospace.com)
  • Let's now compare this FIXX historical PE result, against the recent PE: when this page was posted on 11/16/2023, the most recent closing price for FIXX had been 0.57, and the most recent quarterly earnings result, annualized, was NA. (historicalperatio.com)
  • For self directed investors doing their due diligence on FIXX or any other given stock, valuation analysis for FIXX can greatly benefit from studying the past earnings and resulting PE calculations. (historicalperatio.com)
  • relating to its proposed merger with Q32 Bio, Inc. Under the terms of the agreement, FIXX shareholders are expected to own approximately 25% of the combined company. (kark.com)
  • Under the terms of the agreement, the Group will pay Homology $130 million upfront and invest $50 million to fund Oxford Biomedica Solutions in return for an 80 percent ownership stake, while Homology will own 20 percent of the new company. (oxb.com)
  • As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation? (historicalperatio.com)
  • Homology also shared additional details of the optimized, in vivo gene therapy candidate HMI-204 for metachromatic leukodystrophy (MLD) during the 19th Annual WORLDSymposiumâ„¢ Meeting. (advfn.com)
  • Dr. Seymour continued, "Also at WORLD, we presented the details of our optimized gene therapy development candidate for MLD, which showed the ability to cross the blood-brain-barrier following a single I.V. administration in the murine disease model and resulted in levels of enzyme activity predicted to lead to efficacy in vivo. (advfn.com)
  • As a result of the agreement, which is immediately accretive to the Group's revenue growth with contribution from Homology and future customer pipeline, Oxford Biomedica will establish a presence in the US and will offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. (oxb.com)
  • and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. (globenewswire.com)
  • These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. (homologymedicines.com)
  • These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under "Summary Risk Factors" below and in the sections in this Quarterly Report titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations. (homologymedicines.com)
  • Keros Therapeutics Inc KROS announced preliminary topline results from Part 1 of its Phase 1 trial evaluating single and multiple ascending doses of KER-012 in healthy postmenopausal volunteers. (benzinga.com)
  • $SCYX +2.8% SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences. (bpiq.com)
  • $VBI +0.7% VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open. (bpiq.com)
  • Additionally, at any time following the three-year anniversary of the agreement, the Group will have a call option to purchase, and Homology will have a put option to require the Group to purchase, Homology's ownership interest in Oxford Biomedica Solutions. (oxb.com)
  • We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. (homologymedicines.com)
  • What is the average historical PE for FIXX based on annualized quarterly earnings? (historicalperatio.com)
  • What is the average historical PE for FIXX based on trailing twelve month earnings? (historicalperatio.com)
  • Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the 'E' value at each measurement period, the average FIXX historical PE based on this TTM earnings result method is NA. (historicalperatio.com)
  • FIXX reports an average of 493.49% for its upside potential over the past 37 weeks. (stocknews.com)
  • FIXX has a higher upside potential (average analyst target price relative to current price) than 2543.73% of all US stocks. (stocknews.com)
  • And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for FIXX. (historicalperatio.com)
  • Prior results do not guarantee a similar outcome with respect to any future matter. (kark.com)
  • $BLRX +8.8% BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization. (bpiq.com)
  • To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. (globenewswire.com)
  • You may want to consider a long position or call options on GREE as a result. (tickeron.com)
  • Our investments in Homology, Vedanta, Trillium, and ESSA reflect our commitment to find new and creative ways to leverage Pfizer's resources to deliver breakthroughs to patients. (pfizer.com.sg)
  • If you purchased Homology securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. (globenewswire.com)
  • As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized? (historicalperatio.com)
  • Our pipeline candidates are working to address significant unmet public health and medical needs - from a highly-contagious infectious disease putting hundreds of millions of people at risk worldwide, to a fast-growing cancer that typically results in death within 15 months of diagnosis. (vbivaccines.com)
  • Q32 Bio will be commencing an open-label Phase 2 basket clinical trial, with initial data expected by year-end 2024, and a Phase 2 clinical trial in ANCA-Associated Vasculitis (AAV), with topline results from the AAV and basket trials expected in the second half of 2025. (pipelinereview.com)
  • The decreased risk of metabolic syndrome in extremely obese patients with CMV infection is a surprising result. (vbivaccines.com)
  • Dr. Seymour continued, "Also at WORLD, we presented the details of our optimized gene therapy development candidate for MLD, which showed the ability to cross the blood-brain-barrier following a single I.V. administration in the murine disease model and resulted in levels of enzyme activity predicted to lead to efficacy in vivo. (advfn.com)
  • These results indicate that higher levels of anti-gB antibodies could play an important role in cancer immunotherapy. (vbivaccines.com)